Table 7.
Characteristics of 15 Virologic Failures to Treatment.
| Patient | Age | GT | F, CP | Regimen | History of Previous Therapy | Baseline HCV RNA × 106 IU/mL |
Treatment Course | EOT | Comment (Possible Reason of Failure) |
|---|---|---|---|---|---|---|---|---|---|
| Male 1 | 48 | 1B | 1 | GZR/EBR, 12 wks | treatment-naive | 6.07 | according to schedule | TND | |
| Male 2 | 44 | 1B | 1 | OBV/PTV/r + DSV, 8 wks | treatment-naive | 1.53 | according to schedule | TND | |
| Male 3 | 56 | 1B | 2 | ASV + DCV, 24 wks |
treatment-naive | 1.59 | according to schedule | TD | |
| Male 4 | 59 | 1B | 4, CP-A | OBV/PTV/r + DSV + RBV, 12 wks | non-responder (TVR + pegIFN + RBV) | 0.58 | according to schedule | TD | liver cirrhosis, non-response to previous therapy, liver cirrhosis |
| Male 5 | 59 | 1B | 4, CP-A | LDV/SOF + RBV, 12 wks | relapser (OBV/PTV/r + DSV + RBV) | 1.65 | according to schedule | TND | liver cirrhosis, non-response to the previous therapy, liver cirrhosis |
| Male 6 | 54 | 1B | 4, CP-B | LDV/SOF + RBV, 12 wks | treatment-naive | 0.25 | according to schedule | TND | decompensated liver cirrhosis |
| Male 7 | 31 | 1B | 1 | GLE/PIB, 8 wks | treatment-naive | 0.53 | modified | TD | no adherence (irregular use of the drug due to alcohol abuse) |
| Male 8 | 48 | 1B | 4, CP-B | VEL/SOF + RBV, 12 wks | treatment-naive | 0.31 | according to schedule | TND | decompensated liver cirrhosis |
| Male 9 | 54 | 3 | 4, CP-A | GLE/PIB, 16 wks | relapser (SOF + RBV) | 4.03 | according to schedule | TND | liver cirrhosis, non-response to previous therapy |
| Male 10 | 48 | 4 | 1 | OBV/PTV/r + RBV, 12 wks | relapser (SMV + PegIFN + RBV) | 3.6 | according to schedule | TND | liver cirrhosis, non-response to previous therapy, no adherence to the current treatment |
| Male 11 | 55 | 3 | 4, CP-B | SOF + RBV, 24 wks | non-responder (PegIFN + RBV) | 0.43 | according to schedule | TND | decompensated liver cirrhosis, non-response to previous therapy |
| Male 12 | 52 | 3 | 4, CP-A | SOF + RBV, 24 wks | discontinuation due to safety reason (IFN + RBV) | 0.5 | according to schedule | TND | liver cirrhosis |
| Male 13 | 56 | 3 | 4, CP-A | VEL/SOF + RBV, 24 wks | relapser (GLE/PIB) | 1.08 | according to schedule | TND | liver cirrhosis, non-response to the previous therapy |
| Male 14 | 34 | 3 | 1 | GLE/PIB, 8 wks | treatment-naive | 10.0 | according to schedule | TND | |
| Male 15 | 42 | 3 | 1 | GLE/PIB, 8 wks | treatment-naive | 4.57 | according to schedule | TND |
ASV: asunaprevir; CP: Child–Pugh scale; DCV: daclatasvir; DSV: dasabuvir; EBR: elbasvir; EOT: end of treatment; F: fibrosis; GLE: glecaprevir; GT: genotype; GZR: grazoprevir; HCV RNA: hepatitis C virus ribonucleic acid; LDV: ledipasvir; OBV: ombitasvir; pegIFN: pegylated interferon; PIB: pibrentasvir; PTV/r: paritaprevir; RBV: ribavirin; SMV: simeprevir; SOF: sofosbuvir; TD: target detected; TND: target not detected; TVR: telaprevir; VEL: velpatasvir; wks, weeks.